997 related articles for article (PubMed ID: 28673391)
1. The Development and Use of Janus Kinase 2 Inhibitors for the Treatment of Myeloproliferative Neoplasms.
Hobbs GS; Rozelle S; Mullally A
Hematol Oncol Clin North Am; 2017 Aug; 31(4):613-626. PubMed ID: 28673391
[TBL] [Abstract][Full Text] [Related]
2. Mechanisms of Resistance to JAK2 Inhibitors in Myeloproliferative Neoplasms.
Meyer SC
Hematol Oncol Clin North Am; 2017 Aug; 31(4):627-642. PubMed ID: 28673392
[TBL] [Abstract][Full Text] [Related]
3. Is there a role for JAK inhibitors in BCR-ABL1-negative myeloproliferative neoplasms other than myelofibrosis?
Pardanani A; Tefferi A
Leuk Lymphoma; 2014 Dec; 55(12):2706-11. PubMed ID: 25520049
[TBL] [Abstract][Full Text] [Related]
4. Myeloproliferative neoplasms: JAK2 signaling pathway as a central target for therapy.
Pasquier F; Cabagnols X; Secardin L; Plo I; Vainchenker W
Clin Lymphoma Myeloma Leuk; 2014 Sep; 14 Suppl():S23-35. PubMed ID: 25486952
[TBL] [Abstract][Full Text] [Related]
5. Recent patents of gene mutation relative to JAK/STAT pathway and their implication in myeloproliferative diseases.
Shi Y; Xu C
Recent Pat DNA Gene Seq; 2008; 2(3):209-13. PubMed ID: 19075958
[TBL] [Abstract][Full Text] [Related]
6. JAK-mutant myeloproliferative neoplasms.
Levine RL
Curr Top Microbiol Immunol; 2012; 355():119-33. PubMed ID: 21823028
[TBL] [Abstract][Full Text] [Related]
7. JAK2 inhibitors: not the next imatinib but researchers see other possibilities.
Garber K
J Natl Cancer Inst; 2009 Jul; 101(14):980-2. PubMed ID: 19584324
[No Abstract] [Full Text] [Related]
8. TG101209, a small molecule JAK2-selective kinase inhibitor potently inhibits myeloproliferative disorder-associated JAK2V617F and MPLW515L/K mutations.
Pardanani A; Hood J; Lasho T; Levine RL; Martin MB; Noronha G; Finke C; Mak CC; Mesa R; Zhu H; Soll R; Gilliland DG; Tefferi A
Leukemia; 2007 Aug; 21(8):1658-68. PubMed ID: 17541402
[TBL] [Abstract][Full Text] [Related]
9. Sensitivity and resistance of JAK2 inhibitors to myeloproliferative neoplasms.
Bhagwat N; Levine RL; Koppikar P
Int J Hematol; 2013 Jun; 97(6):695-702. PubMed ID: 23670175
[TBL] [Abstract][Full Text] [Related]
10. JAK-STAT pathway activation in malignant and nonmalignant cells contributes to MPN pathogenesis and therapeutic response.
Kleppe M; Kwak M; Koppikar P; Riester M; Keller M; Bastian L; Hricik T; Bhagwat N; McKenney AS; Papalexi E; Abdel-Wahab O; Rampal R; Marubayashi S; Chen JJ; Romanet V; Fridman JS; Bromberg J; Teruya-Feldstein J; Murakami M; Radimerski T; Michor F; Fan R; Levine RL
Cancer Discov; 2015 Mar; 5(3):316-31. PubMed ID: 25572172
[TBL] [Abstract][Full Text] [Related]
11. Crizotinib Has Preclinical Efficacy in Philadelphia-Negative Myeloproliferative Neoplasms.
Gurska LM; Okabe R; Schurer A; Tong MM; Soto M; Choi D; Ames K; Glushakow-Smith S; Montoya A; Tein E; Miles LA; Cheng H; Hankey-Giblin P; Levine RL; Goel S; Halmos B; Gritsman K
Clin Cancer Res; 2023 Mar; 29(5):943-956. PubMed ID: 36537918
[TBL] [Abstract][Full Text] [Related]
12. [Novel therapeutics in myeloproliferative neoplasms: beyond JAK inhibitors].
Edahiro Y
Rinsho Ketsueki; 2023; 64(9):970-980. PubMed ID: 37793873
[TBL] [Abstract][Full Text] [Related]
13. Janus kinase inhibitors for the treatment of myeloproliferative neoplasms.
Rosenthal A; Mesa RA
Expert Opin Pharmacother; 2014 Jun; 15(9):1265-76. PubMed ID: 24766055
[TBL] [Abstract][Full Text] [Related]
14. New JAK2 inhibitors for myeloproliferative neoplasms.
Quintás-Cardama A; Verstovsek S
Expert Opin Investig Drugs; 2011 Jul; 20(7):961-72. PubMed ID: 21521147
[TBL] [Abstract][Full Text] [Related]
15. JAK2 inhibitors: are they the solution?
Santos FP; Verstovsek S
Clin Lymphoma Myeloma Leuk; 2011 Jun; 11 Suppl 1(0 1):S28-36. PubMed ID: 22035745
[TBL] [Abstract][Full Text] [Related]
16. CYT387, a selective JAK1/JAK2 inhibitor: in vitro assessment of kinase selectivity and preclinical studies using cell lines and primary cells from polycythemia vera patients.
Pardanani A; Lasho T; Smith G; Burns CJ; Fantino E; Tefferi A
Leukemia; 2009 Aug; 23(8):1441-5. PubMed ID: 19295546
[TBL] [Abstract][Full Text] [Related]
17. Rationale for targeting the PI3K/Akt/mTOR pathway in myeloproliferative neoplasms.
Bartalucci N; Guglielmelli P; Vannucchi AM
Clin Lymphoma Myeloma Leuk; 2013 Sep; 13 Suppl 2():S307-9. PubMed ID: 24290217
[TBL] [Abstract][Full Text] [Related]
18. Myeloproliferative neoplasms 5 years after discovery of JAK2V617F: what is the impact of JAK2 inhibitor therapy?
Tibes R; Mesa RA
Leuk Lymphoma; 2011 Jul; 52(7):1178-87. PubMed ID: 21599574
[TBL] [Abstract][Full Text] [Related]
19. Guidelines for the management of myeloproliferative neoplasms.
Choi CW; Bang SM; Jang S; Jung CW; Kim HJ; Kim HY; Kim SJ; Kim YK; Park J; Won JH
Korean J Intern Med; 2015 Nov; 30(6):771-88. PubMed ID: 26552452
[TBL] [Abstract][Full Text] [Related]
20. JAK inhibitors: pharmacology and clinical activity in chronic myeloprolipherative neoplasms.
Treliński J; Robak T
Curr Med Chem; 2013; 20(9):1147-61. PubMed ID: 23317159
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]